(Q34503157)

2 August 2017

0 references

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (English)

1 reference

idiopathic pulmonary fibrosis

2 August 2017

1 reference

1 reference

4

Ulrich Costabel

1 reference

2 August 2017

Dominique Valeyre

1

1 reference

2 August 2017

Carlo Albera

2

1 reference

2 August 2017

Williamson Z Bradford

3

1 reference

2 August 2017

Talmadge E King

5

1 reference

2 August 2017

Jonathan A Leff

6

1 reference

2 August 2017

Paul W Noble

7

1 reference

2 August 2017

Steven A Sahn

8

1 reference

2 August 2017

Roland M du Bois

9

1 reference

2 August 2017

publication date

18 May 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

740-747

1 reference

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Non-steroid agents for idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Pirfenidone in idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

The clinical course of patients with idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230393

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FRESP.12297

Hy's law: predicting serious hepatotoxicity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24836849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24836849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24836849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/RESP.12297

1 reference

2 August 2017

1 reference

2 August 2017

1 reference